Introducing OncoHelix: Revolutionizing Precision Health Services
May 24, 2023
Introducing OncoHelix: Revolutionizing Precision Health Services
May 24, 2023
Show all

Press Release: OncoHelix Canada Announces the Launch of OncoHelix-coLAB in Partnership with Burjeel Holdings at Burjeel Medical City, Abu Dhabi

Calgary, Canada – May 08, 2024: OncoHelix Inc. is proud to announce the official launch of OncoHelix-coLAB, a state-of-the-art laboratory within Burjeel Medical City, Abu Dhabi. This significant event was marked by an inauguration ceremony on May 6, attended by the Canadian Ambassador to the UAE, H.E. Mr. Radha Krishna Panday, emphasizing the strong bi-national cooperation in healthcare innovation between Canada and the UAE.

OncoHelix-coLAB is a partnership between OncoHelix, a leader in precision diagnostics in Canada, and Burjeel Holdings, one of the largest healthcare providers in the UAE. This new, state-of-the-art laboratory located at Burjeel Holdings’ flagship facility, Burjeel Medical City (“BMC”), will specialize in advanced molecular diagnostics and immune profile testing, aiming to significantly enhance patient diagnostics and treatment outcomes in the region.

Dr. Faisal Khan, CEO of OncoHelix, remarked, “This collaboration with Burjeel Holdings is not just a milestone for OncoHelix but a leap towards transforming the future of healthcare through precision diagnostics. The partnership allows OncoHelix to expand its operations into the Asian market, significantly enhancing its global footprint and market reach. OncoHelix-coLAB is our commitment to integrating our extensive expertise in clinical diagnostics with the integrated healthcare services provided by Burjeel Holdings.”

“OncoHelix-CoLab is a first-of-its-kind facility in the UAE that leverages top-tier global expertise to serve the needs of the region. This ground-breaking facility allows for specialized and sophisticated testing to be conducted locally. By providing comprehensive diagnostic services and analyzing disease pathology at the molecular level, we can deliver more tailored healthcare solutions and enhance patient outcomes. This landmark partnership with OncoHelix positions us to better serve the UAE and MENA region, contributing to improved patient care and the development of tailored healthcare solutions.”  – John Sunil, CEO, Burjeel Holdings.

Dr. Pinaki Bose, EVP of OncoHelix, added, “The inauguration of OncoHelix-coLAB is a pivotal moment in our quest to bring cutting-edge diagnostic solutions closer to patients in the UAE and MENA region. Through our collaboration with Burjeel Holdings, we are set to build testing capacity and reduce dependency on the pack-and-ship model in the region.”

OncoHelix-coLAB is uniquely equipped to provide comprehensive services in cancer genomic profiling, molecular diagnostics, cellular and immunology tests, all tailored to meet the specific healthcare needs of the UAE and the broader MENA region.

We extend our heartfelt thanks to the Canadian Ambassador to the UAE for gracing the event as the chief guest and to Burjeel Holdings for their unwavering support and partnership. This collaboration not only signifies a union of medical excellence across borders but also sets a benchmark for future healthcare innovations.


About OncoHelix

OncoHelix is a Calgary-based organization recognized in Canada and internationally as a leader in precision diagnostics. In collaboration with the Hematology Translational Lab (HTL) at the University of Calgary, OncoHelix has developed impactful precision oncology and immunology pipelines. The OncoHelix team comprises molecular diagnostic specialists, clinical pathologists, medical oncologists, immunologists, and bioinformaticians specializing in esoteric clinical diagnostics and translational research. The OncoHelix team has an exemplary record in translational research with over 375 publications in leading scientific journals, multiple international awards, and impeccable success in translating research into precision diagnostic tests.

About Burjeel Holdings

Burjeel Holdings is a leading provider of comprehensive healthcare services in the UAE, Oman and Saudi Arabia. With 76 assets including a network of hospitals, medical centers, and pharmacies across the region, Burjeel Holdings is a pivotal player in transforming the healthcare landscape in the Gulf. Burjeel Holdings’ brands include Burjeel, Medeor, LLH, Lifecare, PhysioTherabia and Tajmeel. It has 13 JCI-accredited facilities, with a total of 1,708 patient beds across its operations in the UAE and Oman and holds a leading position in the UAE.